Stocks · News reference

Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $298

2026-11-05 15:53:40 UTCBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: 2026-11-05 15:53:40 UTC
Checked: 2026-11-05 16:05:00 UTC
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

Benzinga2026-11-05 20:41:04 UTCBenzinga Newsdesk
TD Cowen Maintains Buy on Revolution Medicines, Raises Price Target to $270
RVMD
Benzinga2026-11-05 19:50:35 UTCBenzinga Newsdesk
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $321
RVMD
Fiscal.ai2026-11-05 19:03:08 UTC
RBC Raises Price Target on Revolution Medicines
Following the company's third-quarter earnings report, RBC increased its price target for Revolution Medicines to $321 from $260 while maintaining an Outperform rating.
RVMD
Benzinga2026-11-05 16:58:29 UTCBenzinga Newsdesk
Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $222
RVMD
Benzinga2026-11-05 16:00:33 UTCBenzinga Newsdesk
Truist Securities Reiterates Buy on Revolution Medicines, Raises Price Target to $261
RVMD
Benzinga2026-11-05 14:31:40 UTCBenzinga Newsdesk
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $340
RVMD